This disclosure relates to heterocyclics as inhibitors of HPK1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that useful for treatment of HPK1 mediated diseases and conditions such as cancer. (I)
这项披露涉及
杂环化合物作为HPK1的
抑制剂,特别涉及公式I的化合物或其药用盐,以及包含该化合物的药物组合物,用于治疗HPK1介导的疾病和状况,如癌症。 (I)